Evidence map›Paper›PMID 42440876›Full record

ArticleRSC medicinal chemistry2026

From dual norepinephrine-dopamine reuptake inhibition to selective dopamine reuptake inhibitors: a case of aromatically substituted

Majlen A Dilweg, Willem Jespers, Ameya S Kasture, Rongfang Liu, Tamara A M Mocking, Jelle G van der Ploeg, Adrianus M M Baselier, Gerard J P van Westen, Thomas Hummel, Sonja Sucic and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Majlen A DilwegDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Willem JespersDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.ORCID https://orcid.org/0000-0002-4951-9220
Ameya S KastureInstitute of Pharmacology, Medical University of Vienna Vienna Austria.ORCID https://orcid.org/0000-0002-2947-4803
Rongfang LiuDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Tamara A M MockingDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Jelle G van der PloegDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Adrianus M M BaselierDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Gerard J P van WestenDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.ORCID https://orcid.org/0000-0003-0717-1817
Thomas HummelDepartment of Neurosciences and Developmental Biology, University of Vienna Vienna Austria.
Sonja SucicInstitute of Pharmacology, Medical University of Vienna Vienna Austria.
Adriaan P IJzermanDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Laura H HeitmanDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Daan van der EsDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.ORCID https://orcid.org/0000-0003-3662-8177

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dopamine (DA) is essential for motor control, mood, motivation, and reward in the central nervous system. It functions through receptor activation and is regulated by the dopamine transporter (DAT, SLC6A3), which manages DA reuptake. DAT dysfunction can lead to abnormal DA levels, associated with conditions like depression, Parkinson's disease, and substance abuse. Current efforts to develop dopamine reuptake inhibitors (DRIs) have resulted in only one approved drug, emphasizing the need for new DRI chemotypes. To address this, we expanded the structure-activity relationship of our previously reported

Identifiers

PMID42440876
PMCPMC13334707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.